Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

R. Suzuki; T. Hideshima; N. Mimura; J. Minami; H. Ohguchi; S. Kikuchi; Y. Yoshida; G. Gorgun; D. Cirstea; F. Cottini; J. Jakubikova; Y. T. Tai; D. Chauhan; P. G. Richardson; N. C. Munshi; T. Utsugi; K. C. Anderson

doi:10.1038/leu.2014.300

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

R. Suzuki
, T. Hideshima
, N. Mimura
, J. Minami
, H. Ohguchi
, S. Kikuchi
, Y. Yoshida
, G. Gorgun
, D. Cirstea
, F. Cottini
, J. Jakubikova
, Y. T. Tai
, D. Chauhan
, P. G. Richardson
, N. C. Munshi
, T. Utsugi
, K. C. Anderson

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	510-514
Number of pages	5
Journal	Leukemia
Volume	29
Issue number	2
DOIs	https://doi.org/10.1038/leu.2014.300
State	Published - Feb 7 2015

Access to Document

10.1038/leu.2014.300

Cite this

Suzuki, R., Hideshima, T., Mimura, N., Minami, J., Ohguchi, H., Kikuchi, S., Yoshida, Y., Gorgun, G., Cirstea, D., Cottini, F., Jakubikova, J., Tai, Y. T., Chauhan, D., Richardson, P. G., Munshi, N. C., Utsugi, T., & Anderson, K. C. (2015). Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia, 29(2), 510-514. https://doi.org/10.1038/leu.2014.300

@article{84d804d702ab416db1f9febc13a0d22a,

title = "Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma",

author = "R. Suzuki and T. Hideshima and N. Mimura and J. Minami and H. Ohguchi and S. Kikuchi and Y. Yoshida and G. Gorgun and D. Cirstea and F. Cottini and J. Jakubikova and Tai, \{Y. T.\} and D. Chauhan and Richardson, \{P. G.\} and Munshi, \{N. C.\} and T. Utsugi and Anderson, \{K. C.\}",

note = "Funding Information: This study was supported by the National Institute of Health Grants (SPORE-P50100707, P01-CA078378, P01-155258 (KCA, NCM), R01-CA050947 (KCA), and R01-178264 (TH, KCA); and SENSHIN Medical Research Foundation (RS). KCA is an American Cancer Society Clinical Research Professor. Funding Information: This work was supported by the National Cancer Institute through R01-CA137116, an American Society of Bone and Mineral Research Career Establishment Award and a Marie Curie Career Integration Grant within the 7th European Community Framework Programme.",

year = "2015",

month = feb,

day = "7",

doi = "10.1038/leu.2014.300",

language = "English",

volume = "29",

pages = "510--514",

journal = "Leukemia",

issn = "0887-6924",

number = "2",

}

Suzuki, R, Hideshima, T, Mimura, N, Minami, J, Ohguchi, H, Kikuchi, S, Yoshida, Y, Gorgun, G, Cirstea, D, Cottini, F, Jakubikova, J, Tai, YT, Chauhan, D, Richardson, PG, Munshi, NC, Utsugi, T & Anderson, KC 2015, 'Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma', Leukemia, vol. 29, no. 2, pp. 510-514. https://doi.org/10.1038/leu.2014.300

TY - JOUR

T1 - Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

AU - Suzuki, R.

AU - Hideshima, T.

AU - Mimura, N.

AU - Minami, J.

AU - Ohguchi, H.

AU - Kikuchi, S.

AU - Yoshida, Y.

AU - Gorgun, G.

AU - Cirstea, D.

AU - Cottini, F.

AU - Jakubikova, J.

AU - Tai, Y. T.

AU - Chauhan, D.

AU - Richardson, P. G.

AU - Munshi, N. C.

AU - Utsugi, T.

AU - Anderson, K. C.

N1 - Funding Information: This study was supported by the National Institute of Health Grants (SPORE-P50100707, P01-CA078378, P01-155258 (KCA, NCM), R01-CA050947 (KCA), and R01-178264 (TH, KCA); and SENSHIN Medical Research Foundation (RS). KCA is an American Cancer Society Clinical Research Professor. Funding Information: This work was supported by the National Cancer Institute through R01-CA137116, an American Society of Bone and Mineral Research Career Establishment Award and a Marie Curie Career Integration Grant within the 7th European Community Framework Programme.

PY - 2015/2/7

Y1 - 2015/2/7

UR - https://www.scopus.com/pages/publications/84922457791

U2 - 10.1038/leu.2014.300

DO - 10.1038/leu.2014.300

M3 - Article

C2 - 25306900

AN - SCOPUS:84922457791

SN - 0887-6924

VL - 29

SP - 510

EP - 514

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Access to Document

Other files and links

Cite this